SARS-CoV-2 inhibitor screening is an essential part of COVID-19 preclinical drug discovery offered by Reaction Biology. As a CRO (contract research organization) we support the drug discovery community in the challenge to identify efficacious COVID-19 drugs with specific assays for SARS-CoV-2 drug testing with the goal to block virus entry and replication.
Our SARS-CoV-2 drug discovery services are available for pharmaceutical companies and medical researchers worldwide. Get in touch with the business development manager assigned to your country today.
The SARS-CoV-2 Spike protein and ACE2 binding assay is used to measure the direct binding of potential therapeutics to the Spike protein receptor-binding domain or ACE2 to determine the kinetics of the interaction or to measure whether the test molecule(s) disrupt the Spike/ACE2 interaction.
We perform this assay at our Malvern, PA facility using surface plasmon resonance (SPR) technology. Our team uses state-of-the-art Biacore 8K units that ensure accurate and comprehensive results. The standard turnaround time is two weeks.
We offer compound screening assays targeting proteases that are essential for SARS-CoV-2 virus entry and replication. These target proteases include ACE2, TMPRSS2, Main Protease (Mpro), PLpro and more.
Our protease assay screening service comprises fluorescence-based activity assays for low and large-scale screening, and for off-target analysis via full protease panel screening.
Beside virus replication drugs are also developed to alleviate COVID-19 symptoms with a variety of targets that are well established for medical treatment:
E Pairo-Castineira et al., Nature, 2020. Genetic mechanisms of critical illness in COVID-19.
Y Qiao et al., PNAS, 2020. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2.
E Weisberg et al., Pharm Res., 2020. Repurposing of Kinase Inhibitors for Treatment of COVID-19.
S Liu et al., CCS Chemistry, 2021. Potential Antiviral Target for SARS-CoV-2: A Key Early Responsive Kinase during Viral Entry.
Repurposing kinase inhibitors to target SARS-CoV-2